Can people with cancer treatments develop osteoporosis?Â
In the UK, it is well-recognised that several types of cancer treatment can lead to a significant decline in bone mineral density, a condition often referred to as ‘cancer treatment-induced bone loss’ (CTIBL). While treatments like chemotherapy, radiotherapy, and hormone therapy are vital for treating the cancer, they can also interfere with the natural balance of bone remodelling. According to the NHS, individuals undergoing treatment for breast or prostate cancer are at a particularly high risk because these therapies often work by reducing the levels of sex hormones that protect the skeleton.
What We’ll Discuss in This Article
- How hormone-depletion therapies impact bone densityÂ
- The effect of chemotherapy on bone-building cellsÂ
- Why radiotherapy can cause localised bone thinningÂ
- UK clinical guidelines: Monitoring bone health during cancer careÂ
- Preventive measures: Bisphosphonates and lifestyle changesÂ
- Long-term skeletal health for cancer survivorsÂ
Hormone therapy: The primary driver of bone loss.
Many common cancers, such as breast and prostate cancer, are ‘hormone-sensitive,’ meaning they use oestrogen or testosterone to grow. Treatments designed to stop these cancers work by lowering these hormone levels, which unfortunately removes the skeleton’s natural protection.
- Aromatase Inhibitors (AIs): Used for breast cancer (e.g., Anastrozole, Letrozole), these drugs lower oestrogen levels in postmenopausal women. In the UK, NICE guidelines recommend bone density monitoring for anyone starting AI therapy.Â
- Androgen Deprivation Therapy (ADT):Â Used for prostate cancer, this reduces testosterone. Because testosterone is vital for male bone health, men on ADT can experience rapid bone thinning.Â
According to the Royal Osteoporosis Society, the rate of bone loss during the first year of hormone therapy can be up to ten times faster than natural age-related loss.
The impact of chemotherapy and steroids.
Beyond hormone therapy, other aspects of cancer treatment can affect the skeleton:
- Chemotherapy: Some chemotherapy drugs can have a direct toxic effect on osteoblasts (bone-building cells). In younger women, chemotherapy can also cause ‘premature ovarian insufficiency,’ leading to early menopause and subsequent bone loss.Â
- Corticosteroids: Steroids (like Dexamethasone or Prednisolone) are often used alongside chemotherapy to reduce nausea or inflammation. As discussed in previous articles, long-term or high-dose steroid use is a leading cause of secondary osteoporosis.Â
Radiotherapy and localised bone thinning.
Radiotherapy uses high-energy rays to destroy cancer cells. While it is targeted, it can sometimes cause localised thinning or damage to the bone in the immediate area being treated. For example, radiotherapy to the pelvic area can increase the risk of ‘pelvic insufficiency fractures’ or hip fractures in the years following treatment.
UK clinical monitoring and bone protection.
Because the risk of bone loss is so high during cancer care, UK oncology teams usually incorporate bone health into the treatment plan:
- Baseline DEXA Scan:Â Many patients will have a bone density scan before or shortly after starting hormone therapy.Â
- FRAX Assessment:Â Doctors use this tool to calculate your fracture risk, specifically noting your cancer treatment as a risk factor.Â
- Bone-Strengthening Medication: Many patients in the UK are prescribed bisphosphonates (like Zoledronic acid or Alendronic acid) or Denosumab alongside their cancer treatment. These drugs not only protect the bones but, in some breast cancer cases, may also reduce the risk of the cancer spreading to the bone.Â
Conclusion
Cancer treatments, particularly hormone-depletion therapies and certain chemotherapies, significantly increase the risk of developing osteoporosis. In the UK, managing bone health is considered a vital part of holistic cancer care. By identifying those at high risk early and using bone-strengthening medications, clinical teams can protect the skeleton while treating the cancer. If you are undergoing cancer treatment and are concerned about your bone strength, it is essential to discuss a bone health review with your oncologist or GP. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Do all breast cancer treatments cause osteoporosis?Â
No, treatments like Tamoxifen can actually have a protective effect on the bones in postmenopausal women, whereas Aromatase Inhibitors tend to cause bone loss.
Will my bones recover once the treatment ends?Â
Bone density may stabilise after treatment, but the bone lost during intensive therapy often does not fully return on its own. Long-term monitoring is usually required.
Should I take extra calcium while on chemotherapy?
The NHS recommends a healthy diet rich in calcium, but you should always check with your oncologist before starting high-dose supplements during active treatment.
Is exercise safe during cancer treatment?
Yes, gentle weight-bearing exercise is often encouraged to help maintain bone and muscle strength, but you should have a plan tailored to your specific energy levels and physical health.
Why did my doctor prescribe a bone injection once every six months?Â
 This is likely Denosumab or Zoledronic acid, which are used to ‘lock in’ your bone density and prevent the rapid thinning caused by hormone-depleting drugs.
Can radiotherapy for prostate cancer affect my hips?Â
If the hip joints are within the ‘field’ of radiation, there is a small increased risk of localised thinning over time. Your radiotherapy team takes great care to minimise this.
Is a DEXA scan safe to have during cancer treatment?Â
Yes, a DEXA scan uses a very low dose of radiation (much less than a standard X-ray) and is a standard part of monitoring bone health for cancer patients in the UK.
Authority Snapshot (E-E-A-T Block)
This article examines the clinical intersection of oncology and skeletal health within the UK healthcare framework. It has been written and reviewed by Dr. Stefan Petrov, a UK-trained physician, to ensure the information is accurate and reflects current NHS, NICE, and Royal Osteoporosis Society standards. The content is designed to help cancer patients and survivors manage their long-term bone health.
